Catalog No.
RVV08802
Expression system
Mammalian Cells
Species reactivity
Human papillomavirus type 16
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
L1, Major capsid protein L1
Concentration
3.01 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03101
Applications
ELISA, Neutralization, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
H16.4G12
All-atom MD simulations of the HPV16 capsid., PMID:40475506
HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopes., PMID:40236113
A novel fluorescence immunoassay for the quantitative detection of HPV16 L1 antibodies in human serum samples using ZnCdSe/ZnS quantum dot-labeled antibodies., PMID:40197040
Molecular epidemiology of human papillomavirus variants in cervical cancer in India., PMID:39913513
[A fluorescence immunochromatography method for detection of human papillomavirus type 16 E6 and L1 proteins]., PMID:39584350
Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16., PMID:39453911
Prevalence of HPV16 L1 protein in oral biopsies: A diagnostic study from Ecuador., PMID:39018933
A validated polyclonal antiserum-based immunoassay for assessment of HPV 16 L1 relative potency., PMID:38340596
Nano-Sized Chimeric Human Papillomavirus-16 L1 Virus-like Particles Displaying Mycobacterium tuberculosis Antigen Ag85B Enhance Ag85B-Specific Immune Responses in Female C57BL/c Mice., PMID:37896900
Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope., PMID:37798448
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice., PMID:37175776
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination., PMID:36922512
Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus., PMID:36922453
Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas., PMID:36680181
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice., PMID:36679860
Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study., PMID:36322543
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development., PMID:36263027
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545
Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway., PMID:35619167
Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women., PMID:35552511
Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer., PMID:34642315
Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy., PMID:34635698
The Synthesis of Main Capsid Protein of Anogenital Type HPV6 L1 in Plant Expression System on the Basis of Tomato Fruits., PMID:34189649
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates., PMID:33802456
Inducible expression of human papillomavirus-16 L1 capsomeres in the plastomes of Nicotiana tabacum: Transplastomic plants develop normal flowers and pollen., PMID:33650709
Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency., PMID:33636291
In silico prediction of T-cell and B-cell epitopes of human papillomavirus type 16 L1 protein., PMID:33624357
Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP., PMID:33573433
Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies., PMID:33493568
Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists., PMID:33309485
Response to: "Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test"., PMID:33254024
Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test., PMID:33249381
Phylogeny and In Silico Structure Analysis of Major Capsid Protein (L1) Human Papillomavirus 45 from Indonesian Isolates., PMID:32986347
Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes., PMID:32967963
Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women., PMID:32727491
DRH1 - a novel blood-based HPV tumour marker., PMID:32535546
Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens., PMID:32510304
The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease., PMID:32133000
Simultaneous quantification of major capsid protein of human papillomavirus 16 and human papillomavirus 18 in multivalent human papillomavirus vaccines by liquid chromatography-tandem mass spectrometry., PMID:32067760
Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines., PMID:31994744
Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated Pichia pastoris Expressing HPV16L1 Protein., PMID:31381497
Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity., PMID:31147274
Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry., PMID:30996086
Post-treatment human papillomavirus antibody kinetics in cervical cancer patients., PMID:30955486
Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity., PMID:30560935
A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses., PMID:30360122
Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid., PMID:30287156
VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris., PMID:30091403
L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine., PMID:29984037
Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16., PMID:29959021
For research use only. Not for human or drug use.
